Sarcoidosis Treatment Guidelines

Introduction to Sarcoidosis Treatment

The European Respiratory Society recommends oral glucocorticoids (prednisone) as the first-line treatment for symptomatic sarcoidosis, typically starting at a dose of 20-40 mg daily unless contraindicated 1
Treatment decisions should be based on the risk of mortality or permanent disability, and significant impairment of quality of life, as suggested by the European Respiratory Journal 2
Nearly half of sarcoidosis patients never require systemic treatment, as the disease may resolve spontaneously, according to the European Respiratory Review 3, 4

The standard initial dose of prednisone is 20-40 mg daily, as recommended by the European Respiratory Review 1
Dose reductions may be needed for patients with diabetes, psychosis, or osteoporosis, as suggested by the European Respiratory Review 1, 5
Allow 3-6 months to assess therapeutic response, and follow-up interval of 3-6 months after steroid initiation, as recommended by the European Respiratory Review 1
The goal is to reduce to the lowest dose that provides satisfactory symptom relief and disease control, according to the European Respiratory Review 1, 6

For improvement, gradually decrease steroid dose to the lowest effective dose, as suggested by the European Respiratory Review 1, 5
For worsening disease, add adjunctive therapy and re-evaluate the diagnosis and treatment plan, as recommended by the European Respiratory Review 1, 5

Methotrexate is the preferred second-line agent, as recommended by the European Respiratory Review 1, 3
Inhaled corticosteroids may be appropriate for symptomatic relief of cough and asthma-like symptoms, but should be discontinued if ineffective or if toxicities develop, as suggested by the European Respiratory Review 1, 5
For patients not at risk for morbidity/mortality and without significant quality of life impairment, no glucocorticoid treatment may be preferred, according to the European Respiratory Journal 2

At least half of patients started on glucocorticoids may still be on treatment 2 years later, as reported by the European Respiratory Journal 2
Lack of response over 3-6 months suggests need for alternative treatment strategy, as recommended by the European Respiratory Review 1